Last reviewed 2026-05-18 · How we verify

Cenicriviroc in mild liver impaired

Tobira Therapeutics, Inc. · Phase 1 active Small molecule Quality 45/100

Cenicriviroc in mild liver impaired is a CCR2/CCR5 dual antagonist Small molecule drug developed by Tobira Therapeutics, Inc.. It is currently in Phase 1 development. Also known as: CVC.

Cenicriviroc blocks CCR2 and CCR5 chemokine receptors, inhibiting inflammatory cell recruitment and fibrosis progression in liver disease.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Cenicriviroc in mild liver impaired
Also known as	CVC
Sponsor	Tobira Therapeutics, Inc.
Drug class	CCR2/CCR5 dual antagonist
Modality	Small molecule
Phase	Phase 1

Mechanism of action

By antagonizing CCR2, cenicriviroc reduces monocyte and macrophage infiltration that drives hepatic inflammation and fibrosis. CCR5 blockade provides additional anti-inflammatory effects. This dual mechanism targets key pathways in chronic liver disease progression.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cenicriviroc in mild liver impaired CI brief — competitive landscape report
Cenicriviroc in mild liver impaired updates RSS · CI watch RSS
Tobira Therapeutics, Inc. portfolio CI

Frequently asked questions about Cenicriviroc in mild liver impaired

What is Cenicriviroc in mild liver impaired?

Cenicriviroc in mild liver impaired is a CCR2/CCR5 dual antagonist drug developed by Tobira Therapeutics, Inc..

How does Cenicriviroc in mild liver impaired work?

Cenicriviroc blocks CCR2 and CCR5 chemokine receptors, inhibiting inflammatory cell recruitment and fibrosis progression in liver disease.

Who makes Cenicriviroc in mild liver impaired?

Cenicriviroc in mild liver impaired is developed by Tobira Therapeutics, Inc. (see full Tobira Therapeutics, Inc. pipeline at /company/tobira-therapeutics-inc).

Is Cenicriviroc in mild liver impaired also known as anything else?

Cenicriviroc in mild liver impaired is also known as CVC.

What drug class is Cenicriviroc in mild liver impaired in?

Cenicriviroc in mild liver impaired belongs to the CCR2/CCR5 dual antagonist class. See all CCR2/CCR5 dual antagonist drugs at /class/ccr2-ccr5-dual-antagonist.

What development phase is Cenicriviroc in mild liver impaired in?

Cenicriviroc in mild liver impaired is in Phase 1.

Drug class: All CCR2/CCR5 dual antagonist drugs
Manufacturer: Tobira Therapeutics, Inc. — full pipeline
Also known as: CVC

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing